NIKI BIOSOLUTIONS INC

NIKINASDAQ

🏆 #5106 by market capUS Equity

$9.05▼ $0.31 (−3.43%)

Live

1h—

24h▼ 3.4%

7d▼ 3.7%

14d▲ 5.7%

30d▲ 11.7%

1y▼ 35.4%

🏦Market Cap

$736,914

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $8.95 – $9.09
52-Week Range: $6.00 – $44.70
Volume: $2.55B
Avg Volume: $2.99B
Shares Outstanding: 81,436
Next Earnings: Oct 17, 2026

Fundamentals Snapshot

Annual Revenue: $63,527
Last Q Revenue: $15,090
P/E Ratio: -0.5
P/S Ratio: 0.0x
EPS (TTM): $-18.54
Dividend Yield: 0.00%

Why Investors Own NIKI

✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
✓Healthy economics — 25% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NIKI BIOSOLUTIONS INC

NIKI

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

2.4%▼ −60.4% YoY

Operating Income

−$2M▼ −52.1% YoY

Free Cash Flow

−$2M▲ +54.4% YoY

About NIKI BIOSOLUTIONS INC

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

🦦